Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.
You may also be interested in...
Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics
The drug developer appears to be making the case for premium pricing by differentiating fidaxomicin for its ability to sustain clinical response and cut costs associated with recurrence.
Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic
Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.
Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic
Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.